It is possible that these drugs target myeloid cells as well as tumor cells and could be used in limited doses in combination with checkpoint inhibitors and other therapeutics.Preclinical studies have demonstrated that transient or combinatorial mTOR inhibition can enhance the efficacy of immune checkpoint blockade therapies, and several combination regimens are being evaluated clinically96,97. This evidence concerns the gene MTOR and neoplasm.